11:23 AM
 | 
Mar 14, 2019
 |  BC Extra  |  Financial News

TCG again backs Surrozen in $50M series B

Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined.

Surrozen Inc. (South San Francisco, Calif.) raised $33 million in a series A in 2017 led by The Column Group,...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >